Diltiazem
- Generic Name
- Diltiazem
- Brand Names
- Cardizem, Cartia, Matzim, Taztia, Tiadylt, Tiazac
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26N2O4S
- CAS Number
- 42399-41-7
- Unique Ingredient Identifier
- EE92BBP03H
- Background
Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolariz...
- Indication
Oral
Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.
Indicated for use to improve exercise tolerance in patients with chronic stable angina.
Indicated for the management of variant angina (Prinzmetal's angina).
Intravenous
...
- Associated Conditions
- Angina Pectoris, Variant, Anginal Pain, Atrial Fibrillation, Atrial Flutter, Chronic Stable Angina Pectoris, Dilated Cardiomyopathies, Idiopathic, Fissure;Anal, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Proteinuria, Pulmonary Hypertension (PH), Leg cramps, Prophylaxis of migraine headaches
- Associated Therapies
- -
Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers
- Conditions
- First Posted Date
- 2002-06-20
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 32
- Registration Number
- NCT00039975
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
- Conditions
Asymptomatic Cardiac Ischemia Pilot (ACIP) Study
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.